Mereo BioPharma Group plc (MREO)
- Previous Close
2.6500 - Open
2.6200 - Bid 2.6000 x 100
- Ask 2.6900 x 100
- Day's Range
2.5340 - 2.6680 - 52 Week Range
0.9200 - 4.3600 - Volume
911,990 - Avg. Volume
1,575,093 - Market Cap (intraday)
370.278M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date Mar 29, 2024 - Apr 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.75
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
www.mereobiopharma.comRecent News: MREO
Performance Overview: MREO
Trailing total returns as of 4/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MREO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MREO
Valuation Measures
Market Cap
371.68M
Enterprise Value
320.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.95
Price/Book (mrq)
7.35
Enterprise Value/Revenue
32.02
Enterprise Value/EBITDA
-12.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-294.66%
Return on Assets (ttm)
-23.57%
Return on Equity (ttm)
-57.81%
Revenue (ttm)
10M
Net Income Avi to Common (ttm)
-29.47M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
57.42M
Total Debt/Equity (mrq)
11.78%
Levered Free Cash Flow (ttm)
-14.17M
Research Analysis: MREO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell